Why the study?
Does hepatic impairment alter the pharmacokinetics of fosinopril compared to healthy volunteers?
Population
18 subjects total: 6 healthy volunteers and 12 patients with alcoholic cirrhosis.
Comparison
Fosinopril 10 mg once daily for 14 days vs Healthy volunteers receiving the same regimen
Design
Cohort
Follow-up
14 days
Authors
Loading...
Fosinopril does not accumulate in patients with hepatic impairment secondary to cirrhosis, suggesting standard starting doses can be safely used in this population.
Does hepatic impairment alter the pharmacokinetics of fosinopril compared to healthy volunteers?
Fosinopril does not accumulate in patients with hepatic impairment secondary to cirrhosis, suggesting standard starting doses can be safely used in this population.
Ford et al. (1995) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: